News for CanSino Biologics Inc. (6185.HK)

PR NewswireSHANGHAI, Jan. 27, 2025 SHANGHAI, Jan. 27, 2025 /PRNewswire/ -- On January 27th, 2025, Beijing Time, Qiming Venture Partners' portfolio company

SHANGHAI, Oct. 26, 2024 /PRNewswire/ -- On October 25th, 2024, Beijing Time, WeRide, a world-leading autonomous driving company and Qiming Venture Partners' portfolio company, began trading on Nasdaq. This marks a historic milestone as both the world's first pure-play autonomous driving company to go public and the first publicly listed Robotaxi company. WeRide (NASDAQ:WRD) offered at $15.5/ADS, representing a market cap of $4.3 billion.

Indonesia plans to run clinical trials of several vaccines to fight surging cases of tuberculosis (TB) this year, with concerns the disease might affect economic growth, ministers said on Monday. - VnExpress International

Recently, CanSinoBIO initiated a Phase Ⅲ clinical trial of its Group ACYW135 Meningococcal Conjugate Vaccine Menhycia®, successfully enrolling its first participant in Indonesia. This trial aims...

UBTech is the first humanoid robot company to go public on HKExQiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015UBTech's listing is Qiming's eighth...

December 18, 2023 - CanSino Biologics Inc. , a leading Chinese biopharmaceutical company with a strong track record in the research, production, and commercialization of groundbreaking...

/PRNewswire/ -- Qiming Venture Partners' portfolio company Tuhu Car, China's leading one-stop car service platform, successfully listed on the Hong Kong Stock...

Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2023. These A Shares will be under lockup for 1105 days starting from 3-AUG-2020 to... -Yesterday at 06:00 pm- MarketScreener

CanSino Biologics Inc. announced that, the Recombinant Zoster Vaccine developed by the Group in co-operation with Vaccitech Limited has received a No Objection Letter for clinical trials from Health...

/PRNewswire/ -- The vaccine research market size is estimated to grow by USD 17.59 billion from 2022 to 2027 at a CAGR of 9.88%, according to Technavio. The...

Fosun Pharma’s revenue grew slightly in the first quarter on its diverse product portfolio, while its net profit soared by 116%.

The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades.

PUTRAJAYA: The National Pharmaceutical Regulatory Agency (NPRA) has approved an application from Solution Biologics Sdn Bhd, regarding the extension o...

Key Takeaways: After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland Sales could surge for the company’s Covid-19 vaccines as China launches a nationwide campaign for a new round of boosters By Molly Wen

After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland.

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.

The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.

Female-founded companies shattered the previous annual deal value record in just the first three quarters of 2021, and outperformed the broader market when it comes to exit size and timing.

/PRNewswire/ -- The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of...